Tirzepatide (brand name Zepbound for weight loss, Mounjaro for diabetes) is the newest and most effective FDA-approved medication for weight loss as of 2026. If you're researching weight loss options in Fort Myers, you've probably seen it mentioned alongside semaglutide (Ozempic/Wegovy). Here's what it is, how it works, and why the clinical data is remarkable.
What Is Tirzepatide?
Tirzepatide is a dual GIP/GLP-1 receptor agonist — a weekly self-injectable peptide developed by Eli Lilly. It works on two distinct hormonal pathways simultaneously, which is why it outperforms all previous weight loss medications in clinical trials.
It was first approved by the FDA for type 2 diabetes management (as Mounjaro) in May 2022. In November 2023, it received FDA approval for chronic weight management (as Zepbound) for adults with BMI ≥30 or BMI ≥27 with at least one weight-related health condition.
How Does Tirzepatide Work?
The GLP-1 Mechanism (Shared With Semaglutide)
GLP-1 (glucagon-like peptide-1) is a gut hormone released after eating. It does four things relevant to weight loss:
- Slows gastric emptying — food stays in your stomach longer, creating sustained satiety
- Reduces appetite signaling in the hypothalamus
- Stimulates insulin release in response to meals (glucose-dependent)
- Suppresses glucagon (reducing liver glucose output)
Semaglutide (Ozempic/Wegovy) is a GLP-1 agonist only. It's highly effective. Tirzepatide does all of this too — but also activates a second pathway.
The GIP Mechanism (Unique to Tirzepatide)
GIP (glucose-dependent insulinotropic polypeptide) is another gut hormone released after eating. GIP receptor activation in adipose (fat) tissue promotes fat breakdown and energy expenditure. It also works in the brain on satiety circuits, amplifying the appetite suppression of GLP-1 activation.
The combination of GIP + GLP-1 agonism creates a synergistic effect — the two pathways reinforce each other in ways that neither achieves alone. This is the mechanistic reason why tirzepatide achieves greater weight loss than semaglutide in head-to-head trials.
Clinical Results: How Much Weight Do Patients Lose?
The SURMOUNT-1 trial (the pivotal Phase 3 trial for tirzepatide for weight loss) enrolled 2,539 adults with obesity or overweight with weight-related health conditions. Results at 72 weeks:
- 5 mg/week dose: Average body weight reduction of 15%
- 10 mg/week dose: Average body weight reduction of 19.5%
- 15 mg/week dose: Average body weight reduction of 20.9%
- Placebo: 3.1% weight reduction
For a 220-pound patient, a 20% reduction = 44 pounds. These are averages — individual results vary, and weight loss compounds with dietary and exercise support.
SURMOUNT-1 Trial: Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 2022.
Read the SURMOUNT-1 Trial →Tirzepatide vs Semaglutide: How Do They Compare?
The SURMOUNT-5 trial directly compared tirzepatide (Zepbound) to semaglutide (Wegovy) at the maximum doses of each. Results published in 2025:
- Tirzepatide 15 mg produced 20.2% mean weight loss vs. semaglutide 2.4 mg producing 13.7% at 72 weeks
- Tirzepatide patients were significantly more likely to achieve 25%+ weight loss (39.4% vs 18.2%)
Both medications are effective. Tirzepatide has a clear efficacy advantage in the published data. However, semaglutide has a longer track record, more prescribers with experience, and may be more appropriate for some patients based on insurance coverage, tolerance, or specific health history.
Side Effects: What to Expect
The most common side effects of tirzepatide are gastrointestinal — nausea, constipation, diarrhea, and vomiting. These are most common during dose escalation (the first few months as doses increase toward the therapeutic range) and typically diminish as the body adapts:
- Nausea: Affects ~30–40% of patients during escalation; typically manageable and resolves with dose stabilization
- Constipation: Common — fiber intake and adequate hydration are important throughout treatment
- Injection site reactions: Mild; rotate sites
- Rare but serious: Pancreatitis, gallbladder disease (increased risk with rapid weight loss), thyroid C-cell tumors (seen in animal models — contraindicated in patients with personal/family history of medullary thyroid carcinoma or MEN2)
Who Qualifies for Tirzepatide in Fort Myers?
At Solace Wellness Aesthetics, Dr. Flávio prescribes tirzepatide as part of a supervised medical weight loss program for patients who meet FDA criteria:
- BMI ≥30 (obesity), OR
- BMI ≥27 with at least one weight-related condition (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea)
- No history of medullary thyroid carcinoma or MEN type 2
- Not pregnant or planning pregnancy during treatment
A comprehensive metabolic panel, thyroid evaluation, and health history review precede any prescription. Tirzepatide is a prescription medication requiring medical supervision — it is not available without a provider assessment at Solace.
Tirzepatide and Aesthetics: The Connection
Rapid weight loss with GLP-1/GIP agonists can affect facial volume — patients sometimes experience what's colloquially called "Ozempic face" (facial hollowing, reduced cheek volume, increased skin laxity). At Solace, patients on weight loss programs are monitored for these changes, and Dr. Flávio coordinates with the aesthetic team for patients who want to address facial volume changes with cheek filler, microneedling for skin tightening, or peptides for lean mass preservation.
Frequently Asked Questions
Is tirzepatide covered by insurance in Florida?
Coverage varies by plan. Zepbound (tirzepatide for weight loss) has better insurance coverage in 2026 than Wegovy did in its early years, but not all commercial plans cover it. Dr. Flávio's team will help determine coverage prior to prescribing. For uninsured patients, manufacturer savings cards and compounded tirzepatide from licensed compounding pharmacies may reduce costs significantly — this is an option Dr. Flávio evaluates case by case based on current FDA guidance.
How do I inject tirzepatide?
Tirzepatide is a once-weekly subcutaneous injection, self-administered with a pre-filled auto-injector pen. Injection sites include the abdomen, thigh, or upper arm. Dr. Flávio provides full instruction at the first prescription appointment. Most patients become comfortable with self-injection within the first 1–2 administrations.
How quickly does tirzepatide start working?
Some appetite suppression is noticeable within the first 1–2 weeks even at the starting dose (2.5 mg). Meaningful weight loss begins at 4–8 weeks, with the most significant progress occurring at months 2–6 as doses escalate. The full 72-week clinical trial weight loss results require consistent treatment for the full duration.
Will I regain weight if I stop tirzepatide?
Most clinical data shows that weight regain occurs after discontinuation of GLP-1/GIP agonists. SURMOUNT-4 trial showed ~50% of the weight loss was regained within 1 year of stopping. This is not a personal failing — it reflects the underlying biology of obesity as a chronic condition. Dr. Flávio discusses long-term management strategy with every patient, including how to build sustainable habits during treatment that improve maintenance outcomes.
Can tirzepatide be combined with other weight loss approaches?
Yes — tirzepatide works best as part of a comprehensive program. At Solace, the medical weight loss protocol includes nutritional guidance, metabolic monitoring, and optional complementary services: peptide therapy (CJC-1295/Ipamorelin for lean mass preservation), vitamin injections (B12, MIC lipotropic for metabolic support), and body sculpting treatments for stubborn areas resistant to medication-driven weight loss.